Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose LevelsBr Med J 1973; 1 doi: http://dx.doi.org/10.1136/bmj.1.5844.13 (Published 06 January 1973) Cite this as: Br Med J 1973;1:13
- H. W. C. Ward
Tamoxifen (ICI 46474) was given by mouth to patients with advanced, recurrent, or metastatic breast carcinoma. At a dosage of 10 mg twice daily 60% of patients showed arrest or reversal of tumour growth. At a dosage of 20 mg twice daily 77% showed arrest or reversal of tumour growth. Side effects were usually trivial and their incidence was the same at both dose levels. No patients showed virilization of fluid retention.